Regeneron is the latest in a string of major drugmakers to make pricing concessions for new and existing medicines under agreements with Trump.

Regeneron is the latest in a string of major drugmakers to make pricing concessions for new and existing medicines under agreements with Trump.

On Thursday, President Donald Trump announced a new drug price deal with Regeneron, the latest company to agree to a new price policy push.

Regeneron will make its newly approved gene therapy available for free in the U.S. The company hasn't yet decided how much it will charge in other countries.